98%
921
2 minutes
20
Background: Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to propose novel quantitative scoring rubrics for IBC diagnosis. In this study, we developed a multi-institutional clinical dataset to test and validate the proposed scoring system.
Methods: IBC (N = 988) and non-IBC (N = 332) cases were identified at 2 institutions with dedicated multidisciplinary IBC programs. The non-IBC cohort included consecutive cT4b and cT4c patients. Standard operating procedures (SOPs) were developed for all ambiguous findings and languages. Three different methods were used for the imputation of missing data, resulting in 3 separate datasets. The sensitivity, specificity, and area under the receiver operator characteristic curve (AUC-ROC) were used to assess the discrimination of the proposed scoring rubric.
Results: The distribution of "true IBC" cases was 19.7% very likely IBC, 49.1% strong possibility of IBC, 0.4% weak possibility of IBC, 0.1% very unlikely IBC, and 30.7% unknown; corresponding groupings for true non-IBC cases were 0.6% very likely IBC, 51.8% strong possibility of IBC, 9.9% weak possibility of IBC, 2.1% very unlikely IBC, and 35.5% unknown. The AUC-ROC values for missing data imputation methods were similar (0.83-0.84); exploratory score refinement improved the AUC-ROC to 0.88-0.89.
Conclusion: Using the largest multi-institutional IBC clinical database to date, the score has been validated and is available for clinical use at https://www.komen.org/ibc-calc to assist health-care providers and their patients in IBC diagnosis. Exploratory score refinement demonstrates the potential to increase specificity; however, any change requires separate validation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342733 | PMC |
http://dx.doi.org/10.1093/jnci/djaf088 | DOI Listing |
Clin Cancer Res
August 2025
Weill Cornell Medicine, New York, NY, United States.
Purpose: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, but distinct treatment strategies are limited. Better characterization of the genomic and transcriptomic landscape is critical to elucidate ILC tumor biology, improve histologic classification, and define precision medicine treatment approaches.
Materials And Methods: We retrospectively analyzed de-identified next-generation sequencing data of 4,613 metastatic patients from the Tempus database including 637 with ILC, 91 with mixed lobular/ductal histology, and 3,885 with invasive breast carcinoma of no special type (IBC-NST).
NPJ Breast Cancer
June 2025
University of Hawai'i Cancer Center Inflammatory Breast Cancer Clinic and Research Program, Honolulu, HI, USA.
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer typically diagnosed at advanced stages. Although many cases initially respond to conventional therapies, IBC remains refractory, with high risk of recurrence due to early dissemination, tumor heterogeneity, and complex microenvironmental factors. Despite advancements in treatment, IBC poses unique challenges, particularly in community healthcare settings, where implementation of current guidelines is often limited by disease complexity and evidence gaps.
View Article and Find Full Text PDFNanotechnology
May 2025
Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
Inflammatory breast cancer (IBC) presents a formidable challenge due to its rapid progression and unique clinical characteristics within the various manifestations of breast cancer. Despite being rare, its aggressive nature demands innovative approaches beyond conventional treatments. Nanomedicine offers exciting possibilities for improving all types of breast cancer therapeutics including IBC.
View Article and Find Full Text PDFBr J Cancer
June 2025
Department IQ Health, Radboud University Medical Center, Nijmegen, Netherlands.
Background: Optimizing breast-screening performance involves minimizing overdiagnosis of prognostically favorable invasive breast cancer (IBC) that does not need immediate recall and underdiagnosis of prognostically unfavorable IBC that is not recalled timely. We investigated whether mammographic features of masses predict prognostically relevant IBC characteristics.
Methods: In a screening cohort, we obtained pathological information of 1587 IBCs presenting as a mass through the nationwide cancer registry and pathology databank.
JAMA Netw Open
April 2025
Tinbergen Institute, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Importance: Insufficient moderate to vigorous physical activity (MVPA) is a risk factor for cardiovascular disease (CVD). Effective interventions are needed to bridge the intention-behavior gap and increase MVPA, especially among women with prior hypertensive pregnancy disorder (HPD).
Objective: To test the effectiveness of two 8-week app-based MVPA interventions (motivation and action) that were based on the integrated behavior change (IBC) model and used evidence-based behavior change techniques from behavioral sciences.